Alzheimer’s patients ‘devastated’ at Medicare limits on drug critics say needs more testing
USA Today (subscription required): Peter Whitehouse, professor of neurology, who was part of a group of experts who called on a new Alzheimer’s medication to be revoked by the FDA, said he expects the Centers for Medicare and Medicaid Services to soften its coverage decision.